Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 1.00 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.95 |
| ▸ | BRD4 | O60885 | 3/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.54 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pj34 SCHEMBL29355630 | 1.00 | PARP1 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL422317 | 1.00 | PARP1 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL29478302 | 0.99 | PARP1 (0.98) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL29419962 | 0.99 | PARP1 (0.98) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL5074001 | 0.99 | PARP1 (0.98) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL31153313 | 0.98 | TRPM2 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL20286631 | 0.89 | PARP1 (0.80) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL4728869 | 0.88 | PARP1 (0.79) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL22023552 | 0.88 | PARP1 (0.79) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL6691492 | 0.86 | PARP1 (0.75) | PARP1TNKSPARP15PARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129163-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-24 | — | — | US | claimed |
| US-20250114450-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-10 | — | — | US | claimed |
| US-20250099467-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2025-03-27 | — | — | US | claimed |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | WISTAR INST (US) | 2025-01-09 | — | — | US | claimed |
| EP-4469086-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2024-12-04 | — | — | EP | claimed |
| US-20240335465-A1 | A NON-CANONICAL SIGNALING ACTIVITY OF CGAMP TRIGGERS DNA DAMAGE RESPONSE SIGNALING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-10-10 | — | — | US | claimed |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | The Wistar Institut of Anatomy and Biology (US) | 2024-07-16 | — | — | US | claimed |
| US-12036218-B2 | Modulators of airway basal cells for the treatment or prevention of lung diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2024-07-16 | — | — | US | claimed |
| EP-4321537-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | Akeso Biopharma, Inc. (CN) | 2024-02-14 | — | — | EP | claimed |
| US-20240041859-A1 | METHODS OF TREATING AND PREVENTING KIDNEY DISEASE | WASHINGTON UNIVERSITY (US) | 2024-02-08 | — | — | US | claimed |
| WO-2023246247-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中山康方生物医药有限公司 | 2023-12-28 | — | — | WO | claimed |
| CN-117257934-A | Pharmaceutical composition and use thereof | 中山康方生物医药有限公司 | 2023-12-22 | — | — | CN | claimed |
| WO-2023147297-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| EP-4190819-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | Akeso Biopharma, Inc. (CN) | 2023-06-07 | — | — | EP | claimed |
| CN-115068603-A | Pharmaceutical combination containing anti-PD-1-anti-VEGFA bispecific antibody and application thereof | 中山康方生物医药有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2022188832-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | 中山康方生物医药有限公司 | 2022-09-15 | — | — | WO | claimed |
| WO-2022178443-A1 | A NON-CANONICAL SIGNALING ACTIVITY OF CGAMP TRIGGERS DNA DAMAGE RESPONSE SIGNALING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-25 | — | — | WO | claimed |
| WO-2022146614-A1 | METHODS OF TREATING AND PREVENTING KIDNEY DISEASE | WASHINGTON UNIVERSITY (US) | 2022-07-07 | — | — | WO | claimed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099467-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | BRAF, CHEK1, CHEK2 | PARP1 238/4885TNKS 440/4885PARP15 589/4885 |
| US-20240041859-A1 | METHODS OF TREATING AND PREVENTING KIDNEY DISEASE | CEP170, PKD1, CSPP1 | PARP1 416/4885TNKS 664/4885PARP15 331/4885 |
| US-20240335465-A1 | A NON-CANONICAL SIGNALING ACTIVITY OF CGAMP TRIGGERS DNA DAMAGE RESPONSE SIGNALING | CGAS, ATM, CHEK2 | PARP1 37/4885TNKS 21/4885PARP15 133/4885 |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | CARM1, EZH2, PRMT1 | PARP1 4/4885TNKS 119/4885PARP15 22/4885 |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | CARM1, EZH2, PRMT1 | PARP1 4/4885TNKS 119/4885PARP15 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.